NovaBay Pharmaceuticals Enters Material Definitive Agreement
Ticker: NBY · Form: 8-K · Filed: Mar 11, 2025 · CIK: 1389545
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
NovaBay just signed a big deal, filing an 8-K on March 11th.
AI Summary
On March 5, 2025, NovaBay Pharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with IRS number 680454536, filed this 8-K report on March 11, 2025. The filing pertains to a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a significant new agreement for NovaBay Pharmaceuticals, which could impact its business operations and financial future.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that are not yet fully understood.
Key Numbers
- 001-33678 — SEC File Number (NovaBay's SEC filing identifier)
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- March 5, 2025 (date) — Earliest event reported
- March 11, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- 680454536 (identifier) — IRS Number
- 2000 Powell Street, Suite 1150 (address) — Principal Executive Offices
- Emeryville, CA (location) — Principal Executive Offices City and State
FAQ
What is the nature of the material definitive agreement entered into by NovaBay Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one was entered into on March 5, 2025.
When was this 8-K filing submitted to the SEC?
The 8-K filing was submitted on March 11, 2025.
What is NovaBay Pharmaceuticals' principal executive office address?
NovaBay Pharmaceuticals' principal executive offices are located at 2000 Powell Street, Suite 1150, Emeryville, CA 94608.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is NovaBay Pharmaceuticals' fiscal year end?
NovaBay Pharmaceuticals' fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 11, 2025 regarding NovaBay Pharmaceuticals, Inc. (NBY).